

## Special Issue

# Prevention and Control of Tick-Borne Diseases: Vaccine Development and Implementation

### Message from the Guest Editors

Ticks transmit a number of microorganisms to both pets and humans. At this point, it is worth mentioning at least some that attract public attention: *Borrelia* species bacteria, tick-borne encephalitis virus, and *Babesia* parasites. Diseases caused by these pathogens are emerging in new territories in many parts of the world. Safe and effective vaccines have been licensed for tick-borne encephalitis (TBE), while Lyme borreliosis is not yet a vaccine-preventable disease. New vaccine development is an important public health issue. The results of numerous research projects have recently been published. Topics include current Lyme disease vaccine progress, TBE vaccination breakthrough cases, molecular aspects of TBE vaccines with relation to other *Flavivirus* genus vaccines, and more. This Special Issue is dedicated to diseases that are transmitted by tick bite. Submissions could include such topics as molecular aspects of vaccine development, the immunogenicity and efficacy of vaccines, immune responses to vaccines, coverage and safety issues, etc.

### Guest Editors

Prof. Dr. Artur Sulik

Department of Pediatric Infectious Diseases, Medical University of Białystok, Białystok, Poland

Dr. Kacper Toczyłowski

Department of Pediatric Infectious Diseases, Medical University of Białystok, Białystok, Poland

### Deadline for manuscript submissions

closed (30 April 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/130780](https://mdpi.com/si/130780)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).